top of page

Genesis Healthcare Becomes A.D.A.M. Innovations, Steering the Next Chapter of AI-Driven Genomics

TOKYO, October 1, 2025 - Genesis Healthcare Co., a pioneer in genomics, AI, and precision health, today announced it is changing its corporate name to A.D.A.M. Innovations. A.D.A.M., which stands for Advanced DNA Artificial Mind, represents a future-forward vision where AI, big data, and genomics converge to transform health, prevention, and care.


Paradigm Shift in Genomics


Since the first human genome was revealed more than 20 years ago, genomics has advanced far beyond the realms of sequencing and testing. Today, the vast volume of genomic data, when combined with exponential computing power and artificial intelligence, is driving unprecedented transformation across the field.


Genomic innovation now stands at the forefront of integrating multi-modal data, from health records and imaging to wearable devices and lifestyle metrics, evolving from static datasets into dynamic, real-time solutions that empower individuals, support life science researchers, and enable medical institutions. This convergence marks a true paradigm shift, redefining how health, prevention, and diagnostics are delivered for the future.


ree

The new corporate name reflects a bold transformation from a genetic testing pioneer to a next-generation platform driven by AI and holistic health insights, drawing on multi-modal and multi-omics data, to usher in a future where health is dynamic, disease can be predicted and prevented, and care becomes truly personalized.


Forward Looking


True to its mission of celebrating humanity, A.D.A.M. Innovations leads a new era in health by transforming genomic data into actionable insights to deliver predictive, preventive, and therapeutic solutions that improve real-world health outcomes and redefine the future of care.


Building on the legacy of Genesis Healthcare, which has completed more than 2.8 million tests and established Japan’s largest genomic database, A.D.A.M. Innovations is advancing Artificial Gene Intelligence (AGI) and integrated multi-modal, multi-omics analytics to unlock new models of prediction, prevention, and therapy across research, clinical, and consumer settings.


“A.D.A.M. Innovations reflects our natural evolution from a genetic testing pioneer to an AI-first genomic ecosystem,” said Michel Mommejat, President of A.D.A.M. Innovations. “Our Tokyo-based teams, laboratory, and data platforms remain the backbone of our work, delivering with the same scientific rigor, ethical governance, and customer confidence, now under our new corporate name.”


This unified vision strengthens expansion and partnerships with healthcare, pharma, academia, the public sector, and adjacent industries, while underscoring our AI-first, platform-driven vision for the future of health.


Strategy for the Next Chapter


  • Data & Intelligence Platform: Scale GenesisGaia as the secure backbone for multi-modal and multi-omics data, model training, research, and privacy-preserving collaboration.

  • AI Products & Services: Expand GeneAI Forecast, Diet Connect, and related offerings to deliver actionable, longitudinal insights for clinicians, researchers, individuals, and product development.

  • Clinical & Diagnostics: Grow advanced services including NGS, RNA-seq, microarrays, and liquid biopsies, integrated with AI analytics for higher signal, faster turnaround, and real-world utility.

  • Translational Innovation: Advance frontier modalities (e.g., CRISPR-Cas9, mRNA, AAV-based therapeutics) through internal R&D and strategic partnerships to bridge from prediction to intervention.

  • Responsible Engagement: Build trusted, consent-driven channels that enable individuals to benefit from their genomic and health data while creating measurable value for healthcare, research, marketing, and adjacent industries.

  • Ethical Governance: Continue leadership in responsible data stewardship, security, and compliance, ensuring trust at population scale.

  • Partner Ecosystem: Expand collaborations with academic institutions, research centers, medical organizations, corporations, and government agencies to accelerate discovery and deployment.


The new corporate name will be effective from November 1, 2025, subject to approval at the upcoming shareholders’ meeting.


For additional information, please visit:


About A.D.A.M. Innovations

Founded in Tokyo, A.D.A.M Innovations, currently Genesis Healthcare Co., is a pioneer in genomics, AI, and precision health solutions. The company develops cutting-edge technologies spanning consumer genetics, clinical diagnostics, and AI-driven R&D data platforms. To date, A.D.A.M Innovations has completed more than 2.8 million genetic tests and maintains the largest R&D genomic database of the Japanese population.


For press and media inquiries, please contact:

 

Media Contact:

Crocker Coulson

+1(646) 652-7185

bottom of page